Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR | Market Cap | 953.17B |
| Revenue (ttm) | 311.31B |
| Net Income (ttm) | 53.68B |
| Shares Out | n/a |
| EPS (ttm) | 64.35 |
| PE Ratio | 17.76 |
| Forward PE | n/a |
| Dividend | 8.00 (0.69%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 2,760,918 |
| Average Volume | 2,092,684 |
| Open | 1,159.25 |
| Previous Close | 1,162.20 |
| Day's Range | 1,140.75 - 1,159.25 |
| 52-Week Range | 1,092.45 - 1,421.49 |
| Beta | 0.35 |
| RSI | 43.49 |
| Earnings Date | May 9, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative th...
Dr Reddy's inks pact with China’s Bio-Thera
Hyderabad: Dr Reddy's Labs (DRL) on Wednesday said its subsidiary, Dr Reddy's Labs SA, entered into commercialisation and licensing agreements with Ch.
Dr Reddy's inks South East Asia commercialisation, licence pacts with China's Bio-Thera for Stelara, Simponi biosimilars
India News: HYDERABAD: Dr Reddy’s Labs on Wednesday said its subsidiary, Dr Reddy’s Labs SA, has entered into commercialisation and licencing agreements with Chin.
Nifty 50 top losers today, March 25: IndusInd Bank, Dr. Reddy’s, Adani Enterprises, Coal India and more
The Indian stock markets experienced a volatile session on March 25, 2025, with benchmark indices closing on a flat note. The BSE Sensex gained a marginal 32.81 points (0.04%) to settle at 78,017.19, ...
Pharma and hospital stocks in focus today: Alembic Pharma, Gland Pharma, Apollo Hospital, Fortis Healthcare, Dr Reddy’s [March 24, 2025]
Pharma and hospital-related stocks are seeing heightened investor interest today, March 24, 2025, following key developments. Alembic Pharma announced the successful completion of a US FDA inspection ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Alvotech & Dr. Reddy’s receive FDA acceptance for AVT03, a proposed biosimilar to Prolia & Xgeva
Dr. Reddy’s Laboratories and Alvotech have announced that the U.S. Food and Drug Administration (FDA) has accepted their 351(k) Biologic License Application (BLA) for AVT03, a proposed biosimilar to P...
Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and...
Nifty 50 top gainers today, March 17: Dr. Reddy’s Laboratories, SBI Life Insurance, Bajaj Finserv, Trent and more
Indian equity markets closed on a positive note on March 17, with benchmark indices registering notable gains. The BSE Sensex climbed 341.04 points or 0.46% to settle at 74,169.95, while the NSE Nifty...
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
Dr. Reddy’s receives USFDA EIR for Hyderabad API facility, inspection classified as ‘VAI’
Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility (C...
Nifty 50 top losers today on February 25: Dr. Reddy’s Laboratories, Hindalco Industries, Trent and more
The Indian share market witnessed a volatile trading session on February 25, 2025. While the BSE Sensex managed to post a modest gain of 147.71 points (0.20%) to close at 74,602.12, the Nifty 50 index...
Nifty 50 top losers today on February 19: Dr. Reddy’s Laboratories, TCS, Infosys and Hindustan Unilever
The Indian stock market witnessed a volatile trading session on February 19, 2024, with the benchmark indices ending marginally lower. The BSE Sensex closed at 75,939.18, down by 28.21 points (-0.04%)...
Dr Reddy’s inks exclusive deal for cancer drug in US, EU
Hyderabad: Dr Reddy's Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma giant Dr Reddy's Laboratories Ltd, entered into a l.
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple myeloma therapy Darzalex. Read more here.
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr...
Dr. Reddy’s signs $131.6 million deal with Henlius to commercialize multiple myeloma biosimilar in US and Europe
Dr. Reddy’s Laboratories Limited has entered a strategic collaboration with Shanghai Henlius Biotech, Inc. for the development and commercialization of HLX15, a biosimilar to Darzalex® and Darzalex Fa...
Nifty 50 top gainers today on February 6: Cipla, ITC Hotels, Dr. Reddy’s Laboratories, HDFC Life and more
The Indian equity markets faced a downward trend on February 6, with major indices ending in the red. The Nifty 50 concluded the session at 23,603.35, experiencing a decline of 138.05 points, or 0.39%...
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue. See why RDY stock is a Buy.
Dr. Reddy's Laboratories Limited 2025 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q3 earnings call.
Nifty 50 top losers today on January 24: Dr. Reddy’s Laboratories, Trent, and Mahindra & Mahindra and more
The Indian stock market experienced a tough trading session on January 24, with both benchmark indices, Sensex and Nifty, closing in the red. As market sentiment took a hit, the Sensex witnessed a dec...
Dr Reddy's Laboratories CEO: 'very positive outlook' for Indian pharma industry despite Trump 2.0
CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be supported by the Trump administration. A strong U.S. dollar is bolstering e...
Dr Reddy’s shares fall over 5% following Q3 FY25 results
Shares of Dr Reddy’s Laboratories dropped by 5.19% to ₹1,222.50 on Friday, January 24, 2025, following the release of its Q3 FY25 financial results. The decline comes despite the company reporting rec...
Dr Reddy’s Q3 Results: CLSA raises FY25-27 revenue and margin estimates; check target price
CLSA raised revenue and margin estimates slightly for FY25-27, citing higher-than-expected growth in the recently acquired NRT portfolio.